Johnson & Johnson (JNJ) Debt to Equity (2008 - 2026)
Johnson & Johnson (JNJ) debt to equity from Dec 28, 2008 to Mar 29, 2026. The current Johnson & Johnson (JNJ) debt to equity is 67.73%. You can export chart.
All data is split-adjusted. You can find the most accurate data from the reports on the SEC official website. We recommend verify information using official company filings before making investment decisions.
Debt to Equity
Debt to Equity
Annual Debt to Equity change of Johnson & Johnson (JNJ)
| Year | Debt to Equity | Change |
|---|---|---|
| 2025 | 50.82% | +12.13% |
| 2024 | 45.32% | +13.96% |
| 2023 | 39.77% | +7.41% |
| 2023 | 37.03% | -14.66% |
| 2022 | 43.39% | -20.27% |
| 2021 | 54.42% | +16.86% |
| 2019 | 46.57% | -8.12% |
| 2018 | 50.68% | -5.23% |
| 2017 | 53.48% | +56.00% |
| 2017 | 34.28% | +22.84% |
| 2016 | 27.91% | +3.98% |
| 2014 | 26.84% | +9.04% |
| 2013 | 24.61% | -1.43% |
| 2012 | 24.97% | -27.53% |
| 2012 | 34.46% | +112.63% |
| 2011 | 16.21% | -0.71% |
| 2010 | 16.32% | -41.46% |
| 2008 | 27.88% | N/A |
Comparison Johnson & Johnson (JNJ) debt to equity with competitors
Johnson & Johnson (JNJ) debt to equity is 67.73%.
| Ticker | Name | Debt to Equity | Upside |
|---|---|---|---|
| SNY | Sanofi | 27.50% | -59.40% |
| BIIB | Biogen Inc | 33.72% | -50.22% |
| PFE | Pfizer Inc | 71.50% | +5.57% |
| AZN | Astrazeneca plc | 71.66% | +5.80% |
| NVO | Novo Nordisk | 72.09% | +6.43% |
| GILD | Gilead Sciences Inc | 94.30% | +39.23% |
| GSK | GSK Plc | 106.74% | +57.60% |
| MRK | Merck & Co Inc | 107.06% | +58.07% |
| NVS | Novartis AG | 122.03% | +80.18% |
| LLY | Lilly(Eli) & Company | 139.02% | +105.25% |
| MDCX | MDCorp | 176.75% | +160.96% |
| MDCXW | Medicus Pharma Ltd warrant | 176.75% | +160.96% |
| GRFS | Grifols SA | 177.15% | +161.56% |
| BMY | Bristol-Myers Squibb Company | 219.95% | +224.75% |
| AMGN | AMGEN Inc | 623.75% | +820.95% |
| OGN | Organon & Company | 948.95% | +1301.08% |